 Antibodies, Bispecific
"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 4 | 0 | 4 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 5 | 0 | 5 | | 2022 | 0 | 2 | 2 | | 2023 | 5 | 0 | 5 | | 2024 | 10 | 1 | 11 | | 2025 | 10 | 1 | 11 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Park JC, Berz D, Sharma MR, Malhotra J, Tolcher AW, Hauke RJ, Call JA, Hamm JT, Sanborn RE, Haas NB, Tsai F, Adkins DR, Camidge DR, Spira AI, Senne L, Kalabus J, O'Neill B, Kinkead H, Garcia J, Massarelli E. Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors. Cancer Res Commun. 2026 02 01; 6(2):374-382.
-
Buckner TW, Carpenter SL, Daoud N, Kempton CL, Lee L, Malec L, McLean TW, Morton P, O'Neill C, Staber JM, Wang M, Croteau SE, Recht M. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia. 2026 Jan-Feb; 32(1):63-70.
-
Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, Mitchell MJ. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc Natl Acad Sci U S A. 2025 Nov 11; 122(45):e2409564122.
-
Brooks TR, Zabor EC, Bedelu YB, Yang X, Karimi YH, Nedved AN, Wang Y, Dave N, Landsburg DJ, Baron K, Hu B, Trotier DC, Pophali PA, Miller J, Grover N, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers E, Sundaram S, Brody JD, McKenna M, Ryu Tiger YK, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza-Morales R, Ho CI, Smith SD, Niu A, Hernandez-Ilizaliturri F, Chinyengetere F, Dave S, Abdel-Razeq N, Moustafa MA, Caimi PF, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025 Oct 30; 146(18):2177-2188.
-
Zannikou M, Duffy JT, Procissi D, Najem H, Levine RN, Thakur A, Hambardzumyan D, Lee-Chang C, Leoni L, Horbinski CM, Simberg D, Zhang B, Heimberger AB, Miska J, Balyasnikova IV. Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models. J Immunother Cancer. 2025 Oct 28; 13(10).
-
Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees M, Costello P, Vazquez Martinez M, Pasvolsky O, Wagner C, Davis JA, Castaneda Puglianini O, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo R, Freeman C, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa M, Midha S, Alsina M, Sborov D, Patel K, Lin Y, Ferreri C, Gagelmann N, Kumar A, Hansen D, Cowan A, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct 23; 146(17):2063-2072.
-
Gross Even-Zohar N, Aumann S, Shaulov A, Haran A, Nachmias B, Lebel E, Lehmann-Werman R, Gatt ME. First case report of talquetamab use in AL amyloidosis. Leuk Lymphoma. 2025 Dec; 66(14):2618-2623.
-
Feng Y, Haupt B, Huynh TT, Meshaw R, Martin-Regalado A, Thakur A, Duffy JT, Alzeer A, Siegel DA, Barnes A, Simberg D, Zalutsky MR, Balyasnikova IV. Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. Clin Cancer Res. 2025 Aug 14; 31(16):3537-3549.
-
Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L. Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trial. Haematologica. 2025 Dec 01; 110(12):2930-2941.
-
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS. A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. Nat Commun. 2025 May 18; 16(1):4617.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|